Who We Are
Profound
knowledge
in antisense oligonucleotide design
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - TGF-β signaling. Precise modulation of TGF-β pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.
Our lead compound, ISTH0036, is in Phase 2a clinical development in Ophthalmology. In addition, Isarna has established a portfolio of antisense compounds addressing three important isoforms of TGF-β to treat fibrotic liver disease, such as NASH, and various forms of cancer.
Learn more about
our TGF-BETA pipeline
03
Clinical Trials
A clinical Phase 2a study in nAMD and DME is ongoing. Details can be found at https://www.clinicaltrialsregister.eu